



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242 Fax: +1-925-223-8243

E-mail: bpgooffice@wjgnet.com <http://www.wjgnet.com>

Name of Journal: *World Journal of Immunology*

ESPS Manuscript NO: 21245

Manuscript Type: Minireviews

Reviewer 1.

A nice review of the clinical and molecular aspects of Sjögren's syndrome is provided in the manuscript. In particular the local chemokine and cytokine production that drives the recruitment and local activation of immune cells which causes injury to the acinar is described. Finally the pathways that are amenable for therapeutic targeting are outlined. Although there is not much new here, this is a nice review of this somewhat unusual disease.

No changes.

Reviewer 2.

This manuscript by Crispin JC et al. describes mechanisms of Sjogren's syndrome. The authors explain the exocrine gland infiltration and the development of a local chronic inflammatory response in sicca symptoms. This manuscript has been given a high enough priority for publication.

No changes.

Reviewer 3.

This manuscript reviewed the immune responses which cause Sjögren's syndrome and discuss the possible future therapeutic strategies against the disease. The review mainly focused on the disease-related T cells and cytokines which they produce. Basically, the manuscript is well written and the references are new and informative. Although cellular immune responses involved in the disease are complicated and the conclusions are not simple, the review is useful to give a rough idea of the cellular immune aspect for the disease. I give some suggestions below.

- First of all, add page numbers through the manuscript. They are convenient for reviewers.

We did it.

Minor points are as follows.

- Page 1. Title. "Sjögren's Syndrome" reads "Sjögren's syndrome". **We did it.**
- Page 3, line 1. "Primary Sjögren's syndrome" should be "Primary Sjögren's syndrome (PSS)". **We did it.**
- Page 3, line 14. "Sjögren's syndrome" reads "Sjögren's syndrome (SS)". **We did it.**
- Page 5, line 1. "lymphoid" seems not adequate. Change the word. **We changed the subtitle to "Local lymphocyte infiltration".**
- Page 6, line 21. "pSS" reads "PSS". **We did it.**
- Page 7, line 4. Add "of" after "differentiation". **We added it.**
- Page 7, line 15. "Sifalimumab and Rontalizumab" reads "sifalimumab and rontalizumab". **We did it.**
- Page 7, line 15. "SLE" reads "systemic lupus erythematosus (SLE)". **We did it.**
- Page 8, line 11. "systemic lupus erythematosus" reads "SLE". **We did it.**

- Page 9, line 15. Explain “abatacept”.
We added the following line: “fusion protein of the extracellular domain of CTLA-4 and human IgG1 (abatacept)”.
- Page 11, line 6. “SSP” reads “PSS”. **We did it.**
- Page 12, line 3. Remove “(SS)”. **We removed it.**
- Page 12, line 5. “complains” reads “complaint”. **We did it.**

Reviewer 4.

In this review paper, the authors discussed the pathogenic role of immune response in Sjögren’s syndrome (SS), especially for chemokine and cytokine. And they also discussed the potentiality of those factors as therapeutic targets. The review is well described and is valuable for readers. My conclusion is accept.

No changes.

